Neuropathic component of pain in cancer

Jung Hun Kang; Eduardo Bruera

doi:10.1007/978-0-85729-230-8_13

Neuropathic component of pain in cancer

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The prevalence of neuropathic pain in cancer patients is increasing as more patients are exposed to neurotoxic chemotherapies including taxane and platinum agents. Up to 40 % of cancer patients may experience neuropathic pain during the course of the disease. The neuropathic cancer pain generally originates from tumour-related and treatment-related causes. Various mechanisms such as mechanical or chemical destruction of neurons, distortion of the surrounding nerve environment, and central sensitisation are involved in the development of neuropathic cancer pain. No single symptom or sign could confirm neuropathic pain, but diagnosis only can be established by a combination of unique symptoms, physical examinations, and appropriate tests. Opioids are recommended as first-line agents for the treatment of neuropathic cancer pain. Antidepressants and anticonvulsants have beneficial effects as adjuvants.

Original language	English (US)
Title of host publication	Cancer Pain
Publisher	Springer-Verlag London Ltd
Pages	165-190
Number of pages	26
ISBN (Electronic)	9780857292308
ISBN (Print)	9780857292292
DOIs	https://doi.org/10.1007/978-0-85729-230-8_13
State	Published - Jan 1 2013

Keywords

Cancer
Central sensitisation
Neuropathic pain
Opioids
Peripheral neuropathies
Pharmaceutical adjuvants

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-0-85729-230-8_13

Cite this

@inbook{3adb9dca127c49ae880162ae00ff4937,

title = "Neuropathic component of pain in cancer",

abstract = "The prevalence of neuropathic pain in cancer patients is increasing as more patients are exposed to neurotoxic chemotherapies including taxane and platinum agents. Up to 40 % of cancer patients may experience neuropathic pain during the course of the disease. The neuropathic cancer pain generally originates from tumour-related and treatment-related causes. Various mechanisms such as mechanical or chemical destruction of neurons, distortion of the surrounding nerve environment, and central sensitisation are involved in the development of neuropathic cancer pain. No single symptom or sign could confirm neuropathic pain, but diagnosis only can be established by a combination of unique symptoms, physical examinations, and appropriate tests. Opioids are recommended as first-line agents for the treatment of neuropathic cancer pain. Antidepressants and anticonvulsants have beneficial effects as adjuvants.",

keywords = "Cancer, Central sensitisation, Neuropathic pain, Opioids, Peripheral neuropathies, Pharmaceutical adjuvants",

author = "Kang, {Jung Hun} and Eduardo Bruera",

note = "Publisher Copyright: {\textcopyright} Springer-Verlag London 2013.",

year = "2013",

month = jan,

day = "1",

doi = "10.1007/978-0-85729-230-8_13",

language = "English (US)",

isbn = "9780857292292",

pages = "165--190",

booktitle = "Cancer Pain",

publisher = "Springer-Verlag London Ltd",

}

TY - CHAP

T1 - Neuropathic component of pain in cancer

AU - Kang, Jung Hun

AU - Bruera, Eduardo

N1 - Publisher Copyright: © Springer-Verlag London 2013.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The prevalence of neuropathic pain in cancer patients is increasing as more patients are exposed to neurotoxic chemotherapies including taxane and platinum agents. Up to 40 % of cancer patients may experience neuropathic pain during the course of the disease. The neuropathic cancer pain generally originates from tumour-related and treatment-related causes. Various mechanisms such as mechanical or chemical destruction of neurons, distortion of the surrounding nerve environment, and central sensitisation are involved in the development of neuropathic cancer pain. No single symptom or sign could confirm neuropathic pain, but diagnosis only can be established by a combination of unique symptoms, physical examinations, and appropriate tests. Opioids are recommended as first-line agents for the treatment of neuropathic cancer pain. Antidepressants and anticonvulsants have beneficial effects as adjuvants.

AB - The prevalence of neuropathic pain in cancer patients is increasing as more patients are exposed to neurotoxic chemotherapies including taxane and platinum agents. Up to 40 % of cancer patients may experience neuropathic pain during the course of the disease. The neuropathic cancer pain generally originates from tumour-related and treatment-related causes. Various mechanisms such as mechanical or chemical destruction of neurons, distortion of the surrounding nerve environment, and central sensitisation are involved in the development of neuropathic cancer pain. No single symptom or sign could confirm neuropathic pain, but diagnosis only can be established by a combination of unique symptoms, physical examinations, and appropriate tests. Opioids are recommended as first-line agents for the treatment of neuropathic cancer pain. Antidepressants and anticonvulsants have beneficial effects as adjuvants.

KW - Cancer

KW - Central sensitisation

KW - Neuropathic pain

KW - Opioids

KW - Peripheral neuropathies

KW - Pharmaceutical adjuvants

UR - http://www.scopus.com/inward/record.url?scp=84948104688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948104688&partnerID=8YFLogxK

U2 - 10.1007/978-0-85729-230-8_13

DO - 10.1007/978-0-85729-230-8_13

M3 - Chapter

AN - SCOPUS:84948104688

SN - 9780857292292

SP - 165

EP - 190

BT - Cancer Pain

PB - Springer-Verlag London Ltd

ER -

Neuropathic component of pain in cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this